Profiling circulating tumor DNA for recurrence prediction and prevention in hepatocellular carcinoma following liver transplantation
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218880 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von De-Zhen Guo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcin…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Transplantation, Liver Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Sensitive biomarkers for recurrence risk stratification, recurrence surveillance and adjuvant therapy guidance are of unmet need for patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT). Herein, we explored the potential of profiling circulating tumor DNA (ctDNA) for prediction and prevention of recurrence in HCC after LT. HCC patients (n = 91) who underwent LT were prospectively enrolled. ctDNA was assayed using next-generation sequencing from perioperative plasma (n = 408). Associations between ctDNA status with clinicopathological parameters, tumor recurrence, and adjuvant treatment effect were analyzed. Higher preoperative ctDNA burden correlated with microvascular invasion (median: 45.0 vs 5.1 MTM/mL, P = 0.003) and recurrence (156.2 vs 7.7 MTM/mL, P < 0.001). ctDNA clearance was noted in 87.7% patients after LT and patients who kept positive postoperative ctDNA showed higher recurrence risk (HR = 8.86, P < 0.001), especially early recurrence (within 1 year; 75.0% vs 10.1%, P < 0.001). During follow-up, positive longitudinal ctDNA was similarly predictive of recurrence (HR = 36.50, P < 0.001). The AUC of longitudinal ctDNA for predicting recurrence was 0.930-significantly higher than alpha-fetoprotein (0.655, P < 0.001). Longitudinal ctDNA detected radiologically evidenced recurrence with a median lead time of 5.1 months compared to standard-of-care surveillance. Among patients who received adjuvant therapy, those with positive postoperative ctDNA could benefit (HR = 0.11, P = 0.003) and those with decreased ctDNA burden following treatment experienced longer interval from ctDNA positivity to recurrence (HR = 0.17, P = 0.006). Serial ctDNA analysis demonstrates strong prognostic value, capable of heralding tumor recurrence prior to radiological recurrence and measuring treatment efficacy. Its integration into clinical practice of HCC provides unique opportunities for adjuvant therapy decision-making following LT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery and Liver Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education…
- International Medical Center (IMC), Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
- Shanghai Medical College, Fudan University, Shanghai, 200032, China.
- Zhongshan-BGI Precision Medical Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China; BGI-Shanghai, Shanghai, 200032, China.
- Tianjin Medical Laboratory, BGI-Tianjin, BGI-Shenzhen, Tianjin, 300308, China.
Zitieren
APA
Guo, D. Z., Zhang, S. Y., Zhang, X. Y., Lin, X. H., Aye, L., Liu, H. C., Wang, X. Y., Gu, Z. J., Fu, X. T., Yang, G. H., Sun, Q. M., He, Y. F., Song, K., Huang, X. W., Liu, W. R., Ding, Z. B., Shi, Y. H., Yang, X. R., Fan, J., …, & Zhou, J. (2026). Profiling circulating tumor DNA for recurrence prediction and prevention in hepatocellular carcinoma following liver transplantation. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218880
Vancouver
Guo DZ, Zhang SY, Zhang XY, Lin XH, Aye L, Liu HC, et al. Profiling circulating tumor DNA for recurrence prediction and prevention in hepatocellular carcinoma following liver transplantation. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218880
BibTeX
@article{Guo2026,
author = {Guo, De-Zhen and Zhang, Shi-Yu and Zhang, Xiang-Yu and Lin, Xia-Hui and Aye, Ling and Liu, Han-Cheng and Wang, Xin-Yin and Gu, Zhu-Jun and Fu, Xiu-Tao and Yang, Guo-Huan and Sun, Qi-Man and He, Yi-Feng and Song, Kang and Huang, Xiao-Wu and Liu, Wei-Ren and Ding, Zhen-Bin and Shi, Ying-Hong and Yang, Xin-Rong and Fan, Jia and Huang, Ao and Zhou, Jian},
title = {Profiling circulating tumor DNA for recurrence prediction and prevention in hepatocellular carcinoma following liver transplantation},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218880}
}
EUVIMED